Headlands Technologies LLC boosted its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 231.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 34,317 shares of the company's stock after buying an additional 23,957 shares during the quarter. Headlands Technologies LLC's holdings in Kenvue were worth $733,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. Grove Bank & Trust raised its holdings in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Kenvue in the 4th quarter valued at about $29,000. SRS Capital Advisors Inc. boosted its stake in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares during the last quarter. Fortitude Family Office LLC raised its position in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after buying an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc raised its holdings in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after acquiring an additional 1,441 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Price Performance
KVUE stock traded down $1.29 during trading hours on Friday, hitting $22.33. 17,763,957 shares of the stock traded hands, compared to its average volume of 16,812,043. The stock has a 50-day simple moving average of $22.59 and a 200 day simple moving average of $22.46. The company has a market cap of $42.68 billion, a P/E ratio of 42.14, a P/E/G ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.
Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.67%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.
Analysts Set New Price Targets
A number of research analysts have recently commented on KVUE shares. Citigroup dropped their price objective on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research note on Wednesday, January 15th. Barclays boosted their price target on Kenvue from $21.00 to $23.00 and gave the company an "equal weight" rating in a research report on Thursday, March 27th. Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Evercore ISI started coverage on shares of Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price on the stock. Finally, UBS Group reduced their price target on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $24.00.
Get Our Latest Analysis on Kenvue
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Recommended Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
